AM.score predicts lung adenocarcinoma outcomes and immunotherapy response in a cohort of 1,720 patients
A Simple Blood Test Could Predict Your Lung Cancer Treatment Success
This preprint describes an observational cohort study involving 1,720 lung adenocarcinoma patients, with validation across additional cohort…
A new blood test score predicts which lung cancer patients will respond to immunotherapy, helping doctors avoid ineffective treatments for a…
Linvoseltamab shows improved outcomes versus real-world standard of care in relapsed/refractory multiple myeloma
New Hope for Myeloma Patients After Three Failed Treatments
A Phase 1/2 study with an external control arm compared linvoseltamab to real-world standard of care in 105 triple-class exposed or refracto…
Patients with multiple myeloma who failed three prior treatments show higher response rates and longer survival with linvoseltamab compared …
PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme
A Simple Brain Tumor Test Could Predict Your Treatment Path
This prospective observational cohort study evaluated PINK1 expression in adults (18+ years) with newly diagnosed IDH-wild type glioblastoma…
A specific protein in glioblastoma tissue could forecast survival odds, helping patients plan care even though the test is not available yet…
Anti-BCMA CAR T-cell therapy bb21217 with bb007 showed 69.4% response in relapsed multiple myeloma
Memory Cells Make CAR T Last Longer
This Phase I study evaluated anti-B-cell maturation antigen CAR T-cell therapy bb21217 manufactured with the phosphoinositide 3-kinase inhib…
CAR T cells trained to act like long-term guards may keep multiple myeloma away for years instead of burning out quickly after initial treat…
Pathologic features predict rapid recurrence in T1 melanoma patients across 14 sites
Why Thin Melanomas Kill Older Adults
This observational review analyzed 442 patients with T1 melanoma from 14 sites to identify predictors of rapid recurrence.
Doctors now know that thin melanomas can be deadly for older adults if they return within two years, requiring closer monitoring than previo…
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer
FDA approves a new treatment for advanced prostate cancer called Pluvicto
The FDA has approved Pluvicto, a radioligand therapeutic agent, for the treatment of adult patients with PSMA-positive metastatic castration…
FDA approves Pluvicto, a targeted radiation therapy for advanced prostate cancer that has spread and stopped responding to standard hormone …
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for Prevention of Chemotherapy-Induced and Postoperative Nausea/Vomiting
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery
FDA approved ondansetron injection for prevention of nausea/vomiting associated with emetogenic cancer chemotherapy and postoperative nausea…
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery.
Digital and AI-supported psychosocial interventions modestly reduce distress and improve quality of life in women with breast cancer
Digital mental health tools may help breast cancer patients feel better
This systematic review and meta-analysis of randomized controlled trials evaluated digital and AI-supported psychosocial interventions in wo…
Digital mental health tools using AI and mindfulness help breast cancer patients reduce stress, anxiety, and depression while improving dail…
Adjuvant immune checkpoint inhibitors after curative HCC treatment associated with reduced recurrence risk
Adjuvant Immune Checkpoint Inhibitors May Reduce Liver Cancer Recurrence Risk
A meta-analysis of 3,478 patients with curatively treated hepatocellular carcinoma found adjuvant immune checkpoint inhibitor-based treatmen…
Adding immune checkpoint inhibitors after surgery or ablation significantly lowers the risk of liver cancer returning, giving patients a str…
Network meta-analysis compares 5-HT3 antagonists with or without dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting
New analysis suggests palonosetron plus dexamethasone may reduce delayed vomiting in chemotherapy patients
This network meta-analysis evaluated 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone in patients undergoing…
Combining palonosetron with dexamethasone reduces delayed vomiting in chemotherapy patients better than other common drug options.
Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles
New analysis suggests specific chemo schedules may improve outcomes for early breast cancer patients
This network meta-analysis evaluated Phase II and Phase III trials involving 17,187 women with early-stage breast cancer receiving adjuvant…
A new analysis of 17,187 women with early breast cancer suggests specific chemo schedules may improve outcomes and reduce side effects.
Eight-week mindfulness-based stress reduction reduced fatigue, anxiety, and depression in non-small cell lung cancer patients
Mindfulness training helped lung cancer patients feel less tired and anxious after surgery
This randomized controlled trial evaluated an eight-week mindfulness-based stress reduction program in 80 non-small cell lung cancer patient…
An eight-week mindfulness program helped lung cancer patients feel less tired and anxious during recovery from surgery and chemotherapy.